{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T05:47:10Z","timestamp":1782798430791,"version":"3.54.5"},"reference-count":97,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013412","name":"Sanofi Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013412","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>High-dose (HD) influenza vaccines have demonstrated robust effectiveness in preventing severe influenza-related outcomes, including pneumonia, cardiorespiratory complications, and mortality, with evidence from randomized clinical trials, meta-analyses, and real-world studies consistently showing superiority over standard-dose (SD) vaccines and supporting international recommendations for adults aged \u226560 years. This is increasingly relevant in the context of global aging and immunosenescence, which weakens vaccine-induced immune responses and heightens biological frailty, functional decline, and the risk of severe complications in older adults, especially those with comorbidities. The objective of this work is to describe the introduction, uptake, and current use of HD influenza vaccines in Spain and to summarize the evidence supporting their broader adoption in adults \u226560 years of age. Methods include a narrative synthesis of clinical evidence and an analysis of vaccination strategies implemented across Spanish autonomous communities since the introduction of HD vaccines during the COVID-19 pandemic. Available evidence supports extending HD vaccine use as a population-based strategy to enhance protection and promote equitable access. The results show that the incorporation of HD influenza vaccines marked a significant shift in national vaccination strategies, with heterogeneous uptake across regions: while some prioritized institutionalized or dependent populations, others implemented mixed approaches that also included community-dwelling adults aged \u226560 years. In conclusion, a clear trend toward wider adoption is emerging, with an increasing number of autonomous communities incorporating HD vaccines into their programs and progressively lowering the recommended age threshold, in alignment with international guidance and the biological rationale for strengthened protection in older adults.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1843611","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T05:40:26Z","timestamp":1782798026000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["State-of-the-art of the high dose influenza vaccine in Spain"],"prefix":"10.3389","volume":"17","author":[{"given":"Iv\u00e1n","family":"Sanz-Mu\u00f1oz","sequence":"first","affiliation":[{"name":"National Influenza Centre","place":["Valladolid, Spain"]},{"name":"Instituto de Estudios de Ciencias de la Salud de Castilla y Le\u00f3n, ICSCYL","place":["Soria, Spain"]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC)","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manel","family":"Farre-Avella","sequence":"additional","affiliation":[{"name":"Sanofi","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo J.","family":"Barroso-Santos","sequence":"additional","affiliation":[{"name":"Sanofi","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M.","family":"Eiros","sequence":"additional","affiliation":[{"name":"National Influenza Centre","place":["Valladolid, Spain"]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC)","place":["Madrid, Spain"]},{"name":"Servicio de Microbiolog\u00eda, Hospital Cl\u00ednico Universitario de Valladolid","place":["Valladolid, Spain"]},{"name":"Servicio de Microbiolog\u00eda, Hospital Universitario R\u00edo Hortega","place":["Valladolid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1289\/ehp.1002383","article-title":"Global influenza seasonality: reconciling patterns across temperate and tropical regions","volume":"119","author":"Tamerius","year":"2011","journal-title":"Environ Health Perspect"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33293-2","article-title":"Estimates of global seasonal influenza-associated respiratory mortality: a modelling study","volume":"391","author":"Iuliano","year":"2018","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(18)30496-X","article-title":"Mortality, morbidity, and hospitalisations due to influenza lower respiratory tract infections, 2017: an analysis for the Global Burden of Disease Study 2017","volume":"7","author":"Troeger","year":"2019","journal-title":"Lancet Respir Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2440206","article-title":"Disease burden of influenza in Spain: a five-season study (2015\u20132020)","volume":"21","author":"Sanz-Mu\u00f1oz","year":"2024","journal-title":"Hum Vaccin Immunother"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268823001620","article-title":"Influenza hospitalisations in Spain between the last influenza and COVID-19 pandemic (2009\u20132019)","volume":"151","author":"Canelas-Fern\u00e1ndez","year":"2023","journal-title":"Epidemiol Infect"},{"key":"B6","unstructured":"Carga De Enfermedad De La Gripe Estacional E Impacto De La Vacuna Antigripal\n          \n          2020"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0210353","article-title":"Risk factors associated with severe outcomes in adult hospitalized patients according to influenza type and subtype","volume":"14","author":"Mart\u00ednez","year":"2019","journal-title":"PloS One"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.rce.2020.06.009","article-title":"La gripe y su impacto en la mortalidad","volume":"221","author":"Eiros Bouza","year":"2021","journal-title":"Rev Clin Esp"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1701794","DOI":"10.1183\/13993003.01794-2017","article-title":"Laboratory-confirmed respiratory infections as triggers for acute myocardial infarction and stroke: a self-controlled case series analysis of national linked datasets from Scotland","volume":"51","author":"Warren-Gash","year":"2018","journal-title":"Eur Respir J"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1053","article-title":"Individual-level association of influenza infection with subsequent pneumonia: a case-control and prospective cohort study","volume":"73","author":"Kubale","year":"2021","journal-title":"Clin Infect Dis"},{"key":"B11","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1177\/1932296819883340","article-title":"Quantifying the impact of influenza among persons with type 2 diabetes mellitus: a new approach to determine medical and physical activity impact","volume":"15","author":"Samson","year":"2021","journal-title":"J Diabetes Sci Technol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500245","article-title":"Community-acquired pneumonia requiring hospitalization among U.S. adults","volume":"373","author":"Jain","year":"2015","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/irv.12506","article-title":"Effects of seasonal and pandemic influenza on health\u2010related quality of life, work and school absence in England: results from the Flu Watch cohort study","volume":"12","author":"Fragaszy","year":"2018","journal-title":"Influenza Other Respir Viruses"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1186\/s12979-020-00181-1","article-title":"The immune response to influenza in older humans: beyond immune senescence","volume":"17","author":"McElhaney","year":"2020","journal-title":"Immun Ageing"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2018.23.16.17-00454","article-title":"Impact of infectious diseases on population health using incidence-based disability-adjusted life years (DALYs): results from the Burden of Communicable Diseases in Europe study, European Union and European Economic Area countries, 2009 to 2013","volume":"23","author":"Cassini","year":"2018","journal-title":"Eurosurveillance"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02432-1","article-title":"High clinical burden of influenza disease in adults aged \u2265\u200965 years: can we do better? A systematic literature review","volume":"40","author":"Langer","year":"2023","journal-title":"Adv Ther"},{"key":"B17","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1186\/s12877-019-1348-z","article-title":"Disability incidence and functional decline among older adults with major chronic diseases","volume":"19","author":"Fong","year":"2019","journal-title":"BMC Geriatr"},{"key":"B18","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1093\/epirev\/mxs009","article-title":"Multimorbidity in older adults","volume":"35","author":"Salive","year":"2013","journal-title":"Epidemiologic Rev"},{"key":"B19","unstructured":"Flu & People 65 Years and Older\n          \n          2022"},{"key":"B20","unstructured":"Genetic Causes of Adult-Onset Disorders | Learn Science at Scitable"},{"key":"B21","unstructured":"Vacunaci\u00f3n En Poblaci\u00f3n Adulta Ponencia De Programa Y Registro De Vacunaciones Septiembre 2018\n          \n          2018"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-023-01451-2","article-title":"Immunosenescence: molecular mechanisms and diseases","volume":"8","author":"Liu","year":"2023","journal-title":"Sig Transduct Target Ther"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.08.105","article-title":"Antibody response to influenza vaccination in the elderly: a quantitative review","volume":"24","author":"Goodwin","year":"2006","journal-title":"Vaccine"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2012.04.008","article-title":"Innate immunosenescence: effect of aging on cells and receptors of the innate immune system in humans","volume":"24","author":"Solana","year":"2012","journal-title":"Semin Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.mad.2006.11.016","article-title":"Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans","volume":"128","author":"Franceschi","year":"2007","journal-title":"Mech Ageing Dev"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.4110\/in.2019.19.e37","article-title":"Aging and the immune system: the impact of immunosenescence on viral infection, immunity and vaccine immunogenicity","volume":"19","author":"Oh","year":"2019","journal-title":"Immune Netw"},{"key":"B27","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.chom.2019.01.002","article-title":"Influenza virus vaccination elicits poorly adapted B cell responses in elderly individuals","volume":"25","author":"Henry","year":"2019","journal-title":"Cell Host Microbe"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-018-0002-y","article-title":"Influenza","volume":"4","author":"Krammer","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"B29","first-page":"49","article-title":"Original antigenic sin. A confounding issue","volume":"115","author":"Haaheim","year":"2003","journal-title":"Dev Biol (Basel)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0900398","article-title":"Original antigenic sin responses to influenza viruses","volume":"183","author":"Kim","year":"2009","journal-title":"J Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3201\/eid1606.100453","article-title":"The wages of original antigenic sin","volume":"16","author":"Morens","year":"2010","journal-title":"Emerg Infect Dis"},{"key":"B32","article-title":"On the doctrine of original antigenic sin","volume":"104","author":"Francis","year":"1960","journal-title":"Proc Am Philos Soc"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1172\/JCI162192","article-title":"Impact of antigenic evolution and original antigenic sin on SARS-CoV-2 immunity","volume":"133","author":"Aguilar-Bretones","year":"2023","journal-title":"J Clin Invest"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12121314","article-title":"Immunosenescence: aging and immune system decline","volume":"12","author":"Goyani","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2236537","article-title":"Long-term influenza antibodies profiles in previously vaccinated and non-vaccinated adults","volume":"19","author":"Sanz-Mu\u00f1oz","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0256475","article-title":"Prevalence of antibodies against seasonal influenza A and B viruses among older adults in rural Thailand: a cross-sectional study","volume":"16","author":"Suntronwong","year":"2021","journal-title":"PloS One"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2021.101422","article-title":"Immunosenescence and inflammaging in the aging process: age-related diseases or longevity","volume":"71","author":"Santoro","year":"2021","journal-title":"Ageing Res Rev"},{"key":"B38","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s10522-015-9578-8","article-title":"Inflammaging decreases adaptive and innate immune responses in mice and humans","volume":"17","author":"Frasca","year":"2016","journal-title":"Biogerontology"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0034795","article-title":"Human cytomegalovirus entry into dendritic cells occurs via a macropinocytosis-like pathway in a pH-independent and cholesterol-dependent manner","volume":"7","author":"Haspot","year":"2012","journal-title":"PloS One"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2010.10.002","article-title":"Impact of cellular senescence signature on ageing research","volume":"10","author":"Sikora","year":"2011","journal-title":"Ageing Res Rev"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1017\/S0954422408138732","article-title":"Obesity and inflammation: the effects of weight loss","volume":"21","author":"Forsythe","year":"2008","journal-title":"Nutr Res Rev"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.4161\/rna.23144","article-title":"A new role for microRNAs, as ligands of Toll-like receptors","volume":"10","author":"Fabbri","year":"2013","journal-title":"RNA Biol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201343921","article-title":"Circulating mitochondrial DNA increases with age and is a familiar trait: implications for \u00abinflamm-aging\u00bb","volume":"44","author":"Pinti","year":"2014","journal-title":"Eur J Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.01.025","article-title":"You are what you host: microbiome modulation of the aging process","volume":"156","author":"Heintz","year":"2014","journal-title":"Cell"},{"key":"B45","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1159\/000381134","article-title":"Frailty, inflammation and immunosenescence","volume":"41","author":"Fulop","year":"2015","journal-title":"Interdiscip Top Gerontol Geriatr"},{"key":"B46","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1186\/s12877-023-03979-y","article-title":"Association of frailty with influenza and hospitalization due to influenza among independent older adults: a longitudinal study of Japan Gerontological Evaluation Study (JAGES)","volume":"23","author":"Iwai-Saito","year":"2023","journal-title":"BMC Geriatr"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa092","article-title":"Frailty hinders recovery from influenza and acute respiratory illness in older adults","volume":"222","author":"Lees","year":"2020","journal-title":"J Infect Dis"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004876.pub3","article-title":"Vaccines for preventing influenza in the elderly","volume":"17","author":"Jefferson","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.09.063","article-title":"Cochrane re-arranged: support for policies to vaccinate elderly people against influenza","volume":"31","author":"Beyer","year":"2013","journal-title":"Vaccine"},{"key":"B50","volume-title":"High dose influenza vaccine for adults: a review of clinical effectiveness, cost-effectiveness, and guidelines","author":"Wells","year":"2019"},{"key":"B51","unstructured":"Fluzone High-Dose Seasonal Influenza Vaccine\n          \n          2023"},{"key":"B52","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.vaccine.2008.09.092","article-title":"In vitro evidence that commercial influenza vaccines are not similar in their ability to activate human T cell responses","volume":"27","author":"Co","year":"2009","journal-title":"Vaccine"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00717","article-title":"Vaccines to prevent infectious diseases in the older population: Immunological challenges and future perspectives","volume":"11","author":"Wagner","year":"2020","journal-title":"Front Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.03.092","article-title":"Efficacy and safety of high-dose influenza vaccine in elderly adults: A systematic review and meta-analysis","volume":"35","author":"Wilkinson","year":"2017","journal-title":"Vaccine"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315727","article-title":"Efficacy of high-dose versus standard-dose influenza vaccine in older adults","volume":"371","author":"DiazGranados","year":"2014","journal-title":"N Engl J Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2330","article-title":"Systematic review of the efficacy, effectiveness and safety of high-dose seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals \u226518 years of age","volume":"33","author":"Comber","year":"2023","journal-title":"Rev Med Virol"},{"key":"B57","unstructured":"Types of Seasonal Influenza Vaccine\n          \n          2020"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1086\/599790","article-title":"Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older","volume":"200","author":"Falsey","year":"2009","journal-title":"J Infect Dis"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu622","article-title":"Randomized, controlled trial of high-dose influenza vaccine among frail residents of long-term care facilities","volume":"211","author":"Nace","year":"2015","journal-title":"J Infect Dis"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2021.1983387","article-title":"Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial","volume":"17","author":"Pepin","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvacx.2023.100327","article-title":"High-dose influenza vaccine in older adults by age and seasonal characteristics: Systematic review and meta-analysis update","volume":"14","author":"Lee","year":"2023","journal-title":"Vaccine X"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2024.106187","article-title":"The relative vaccine effectiveness of high-dose vs standard-dose influenza vaccines in preventing hospitalization and mortality: A meta-analysis of evidence from randomized trials","volume":"89","author":"Skaarup","year":"2024","journal-title":"J Infect"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2509907","article-title":"High-dose influenza vaccine effectiveness against hospitalization in older adults","volume":"393","author":"Johansen","year":"2025","journal-title":"N Engl J Med"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2509834","article-title":"High-dose influenza vaccine to reduce hospitalizations","volume":"393","author":"Pardo-Seco","year":"2025","journal-title":"N Engl J Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01742-8","article-title":"Effectiveness of high-dose influenza vaccine against hospitalisations in older adults (FLUNITY-HD): an individual-level pooled analysis","volume":"406","author":"Johansen","year":"2025","journal-title":"Lancet"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.12.036","article-title":"Economic evaluation of high-dose inactivated influenza vaccine in adults aged \u226565 years: A systematic literature review","volume":"39","author":"Colrat","year":"2021","journal-title":"Vaccine"},{"key":"B67","unstructured":"JCVI Statement on Influenza Vaccines for 2025 to 2026\n          \n          2024"},{"key":"B68","unstructured":"Statement of Amendment to the Annual Flu Letter for 2024 to 2025 \u2013 12 June 2024\n          \n          2024"},{"key":"B69","unstructured":"Canadian Immunization Guide Chapter on Influenza and Statement on Seasonal Influenza Vaccine for 2023\u20132024\n          \n          2023"},{"key":"B70","unstructured":"Beschluss Und Wissenschaftliche Begr\u00fcndung Zur Anpassung Der STIKO-Empfehlung Einer Standardimpfung F\u00fcr Personen \u2265\u200960 Jahre Zum Schutz Vor Erkrankungen Durch Saisonale Influenzaviren\n          \n          2024"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7432a2","article-title":"Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices - United States, 2025-26 influenza season","volume":"74","author":"Grohskopf","year":"2025","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B72","unstructured":"Influenza (Flu)\n          \n          2023"},{"key":"B73","unstructured":"Acta De La Sesi\u00f3n Celebrada El 17 De Mayo De 2024: Acuerdos Sobre Expedientes De Contrataci\u00f3n, Incluyendo Suministro De Vacuna Antigripal Para La Campa\u00f1a 2024-2025 (Expediente 2201\/2024)\n          \n          2024"},{"key":"B74","unstructured":"Resoluci\u00f3n De La Directora Gerente Del Servicio Aragon\u00e9s De Salud Por La Que Se Adjudica El Suministro De Vacunas Frente a La Gripe Estacional Para La Campa\u00f1a 2024-2025 Destinadas a La Poblaci\u00f3n De Arag\u00f3n, Contrato Derivado De Acuerdo Marco (Exp. SAS-SGE-2024-22)\n          \n          2024"},{"key":"B75","unstructured":"Resoluci\u00f3n Por La Que Se Adjudica El Contrato Del Suministro De Vacunas Frente a La Gripe Estacional \u2013 Campa\u00f1a 2024 (Lotes: 1, 3, 4 Y 5) Basado En El Acuerdo Marco 202101AM0001 Y Se Dispone El Gasto Preciso Para Su Financiaci\u00f3n\n          \n          2024"},{"key":"B76","unstructured":"Campa\u00f1a De Vacunaci\u00f3n Frente a Gripe Y COVID. Temporada 2024-2025\n          \n          2024"},{"key":"B77","unstructured":"Resoluci\u00f3n 10.2.17\/24 CBAM-SGSAL-2024-002: Contrato Derivado De Acuerdo Marco Estatal Para Adquisici\u00f3n De Vacunas De Gripe Estacional Para La Campa\u00f1a 2024-2025 Para La Comunidad Aut\u00f3noma De Cantabria\n          \n          2024"},{"key":"B78","unstructured":"Acta N\n          \n          2024"},{"key":"B79","unstructured":"Instrucci\u00f3n T\u00e9cnica Campa\u00f1a Gripe Y COVID-19 2024-2025\n          \n          2024"},{"key":"B80","unstructured":"Campanya De Vacunaci\u00f3 Tardor 2024-25: Vacunaci\u00f3 Contra La Grip I La COVID-19\n          \n          2024"},{"key":"B81","unstructured":"Resoluci\u00f3n De Adjudicaci\u00f3n: Adquisici\u00f3n De 130.000 Dosis De Vacunas Inactivadas Frente a La Gripe Estacional Para La Campa\u00f1a 2024-2025 En La Comunidad Aut\u00f3noma De Extremadura, Ejecuci\u00f3n Del Acuerdo Marco 202101AM0001, Lote 4\n          \n          2024"},{"key":"B82","unstructured":"Resoluci\u00f3n De Adjudicaci\u00f3n Del Contrato Para El Suministro Sucesivo De Vacuna Antigripal De Alta Carga (Efluelda) Para El Programa Gallego De Vacunaci\u00f3n\n          \n          2024"},{"key":"B83","unstructured":"Protocolo Campa\u00f1a Vacunaci\u00f3n Gripe Y COVID-19 2024-2025\n          \n          2024"},{"key":"B84","unstructured":"Protocolo T\u00e9cnico De Los Contratos Basados En El Acuerdo Marco 202101AM0001 Para El Suministro De Vacunas Frente a La Gripe Estacional. Campa\u00f1a 2024-2025\n          \n          2024"},{"key":"B85","unstructured":"Protocolo De Vacunaci\u00f3n Estacional Frente a Infecciones Respiratorias (Gripe Y COVID-19) Temporada 2024-2025\n          \n          2024"},{"key":"B86","unstructured":"Resoluci\u00f3n 273\/2024: Adjudicaci\u00f3n Del Contrato De Suministro De Vacuna Antigripal Tetravalente De Alta Carga Antig\u00e9nica Para La Temporada 2024-2025\n          \n          2024"},{"key":"B87","unstructured":"Resoluci\u00f3n De 18 De Septiembre De 2024 Por La Que Se Establece El Comienzo De La Campa\u00f1a De Vacunaci\u00f3n Frente a La Gripe, Temporada 2024-2025\n          \n          2024"},{"key":"B88","unstructured":"Protocolo De Licitaci\u00f3n Del Cuarto Contrato Basado En El Acuerdo Marco Estatal Para La Selecci\u00f3n De Suministradores De Vacunas Frente a La Gripe Estacional"},{"key":"B89","unstructured":"INFORME DE LA DIRECCI\u00d3N GENERAL DE SALUD P\u00daBLICA, CALIDAD E INNOVACI\u00d3N SOBRE LAS DOSIS EFECTIVAS a SUMINISTRAR EN RELACI\u00d3N CON EL \u201cACUERDO MOTIVADO DE DECLARACI\u00d3N DE EMERGENCIA SOBRE LA REALIZACI\u00d3N DE UNA COMPRA EXTRAORDINARIA DE VACUNAS FRENTE a LA GRIPE, PARA LA CAMPA\u00d1A 2020-2021, POR EL MINISTERIO DE SANIDAD, COMO FORMA DE RESPUESTA ANTE LA EMERGENCIA DERIVADA DE LA PANDEMIA DE LA COVID-19\u201d, (Firmado Por El Ministro De Sanidad, Con Fecha 20 De Mayo De 2020)\n          \n          2020"},{"key":"B90","unstructured":"COVID-19 Public Health Emergency of International Concern (2020-23)\n          \n          2023"},{"key":"B91","unstructured":"Ine. Cifras De Poblaci\u00f3n. Datos Definitivos. Poblaci\u00f3n Residente Por Fecha, Sexo Y Edad\n          \n          2022"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.gaceta.2020.02.008","article-title":"Efectividad de la vacuna de la gripe para prevenir casos graves. Temporada 2018\/2019","volume":"35","author":"Gras-Valent\u00ed","year":"2021","journal-title":"Gaceta Sanitaria"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2019.24.1900121","article-title":"Interim 2018\/19 influenza vaccine effectiveness: six European studies, October 2018 to January 2019","volume":"24","author":"Kissling","year":"2019","journal-title":"Eurosurveillance"},{"key":"B94","unstructured":"Factors That Influence Vaccine Effectiveness\n          \n          2024"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0144-2024","article-title":"Influenza vaccine outcomes: a meta-analysis revealing morbidity benefits amid low infection prevention","volume":"34","author":"Presa","year":"2025","journal-title":"Eur Respir Rev"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae631.1458","article-title":"P-1277. Impact of common biases on simulated relative vaccine effectiveness estimates: implications for evidence synthesis, decision making, and real-world studies","volume":"12","author":"Harris","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-026-01894-8","article-title":"Cost-effectiveness analysis of influenza vaccination with high-dose vaccine versus standard-dose quadrivalent vaccine in older adults in Spain","author":"Abellan-Perpi\u00f1an","year":"2026","journal-title":"Eur J Health Econ"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1843611\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T05:41:21Z","timestamp":1782798081000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1843611\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":97,"alternative-id":["10.3389\/fimmu.2026.1843611"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1843611","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"article-number":"1843611"}}